A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Breast Cancer Clinical Trial

Official title:

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03665285
• Other study ID #: NC318-01
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 1, 2018
• Est. completion date: April 11, 2023

Study information

• Verified date: March 2024
• Source: NextCure, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: April 11, 2023
• Est. primary completion date: April 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged 18 or older.

• Willingness to provide written informed consent for the study.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

• Subjects with advanced unresectable and/or metastatic solid tumors.

• Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. Note: There is no limit to the number of prior treatment regimens.

• Presence of measurable disease based on RECIST v1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other locoregional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.

• Able to provide pretreatment tumor tissue sample at Screening.

• Subjects of childbearing potential (defined as female subjects who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not postmenopausal, defined as = 12 months of amenorrhea not caused by reversible conditions, diseases, or medications) and non-sterilized male subjects must agree to take appropriate precautions to avoid pregnancy or fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug.

Exclusion Criteria:

• Inability to comprehend or unwilling to sign the Informed Consent Form.

• Screening laboratory values of:

1. Absolute neutrophil count < 1.5 × 10^9/L

2. Platelets < 100 × 10^9/L

3. Hemoglobin < 9 g/dL or < 5.6 mmol/L

4. Serum creatinine > 1.5 × institutional upper limit of normal (ULN)

5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 × ULN

6. Total bilirubin > 1.5 × ULN.

7. International normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN or activated partial thromboplastin time (aPTT) > 1.5 × ULN

• Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 7 days before the first administration of study drug.

• Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:

1. = 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Subjects must also not require chronic use of corticosteroids and must not have had radiation pneumonitis because of a treatment. A 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with medical monitor approval. Note: Bisphosphonates and denosumab are permitted medications.

2. = 28 days for prior immunotherapy or persistence of active cellular therapy (e.g., chimeric antigen receptor T cell therapy; other cellular therapies must be discussed with the medical monitor to determine eligibility).

3. = 28 days for a prior monoclonal antibody used for anticancer therapy except for denosumab.

4. = 7 days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted. Note: The use of corticosteroids equivalent to prednisone </= 10mg/day is allowed.

5. = 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational study drugs or devices.

6. = 14 days for COVID-19 vaccine.

• Has not recovered to = Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.

• Receipt of a live vaccine within 30 days of planned start of study therapy.

• Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).

• Known active CNS metastases and/or carcinomatous meningitis.

• Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry after treatment with curative intent.

• Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.

• Documented known activating or driver mutations (i.e. EGFR mutations/amplification, BRAF mutations, ALK alterations, etc.) which have not been previously treated with a standard of care targeted therapy.

• Subjects with screening QTc interval >470 milliseconds are excluded.

• Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment.

• Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless the hepatitis is considered to be cured.

• Known history of HIV (HIV 1 or HIV 2 antibodies).

• Known allergy or reaction to any component of study drug or formulation components.

• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study treatment.

• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Breast Cancer
• Carcinoma
• Cholangiocarcinoma
• CRC
• Endometrial Cancer
• Endometrial Neoplasms
• Head and Neck Squamous Cell Carcinoma
• Lung Cancer
• Melanoma
• Squamous Cell Carcinoma of Head and Neck
• Urothelial Carcinoma

Intervention

Drug:
• NC318
NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Locations

Country	Name	City	State
United States	Pennsylvania Cancer Specialists and Research Institute	Gettysburg	Pennsylvania
United States	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey
United States	The Angeles Clinic and Research Institute	Los Angeles	California
United States	Yale University Cancer Center	New Haven	Connecticut
United States	Laura and Isaac Perlmutter Cancer Center	New York	New York
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
NextCure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0	The number of participants who have had at least one TEAE during the study.	From enrollment through up to 90 days after end of treatment, an average of 1 year
Secondary	Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	To assess antitumor activity/efficacy by evaluating objective response rate (ORR), defined as the percentage of participants who experienced a complete response (CR; disappearance of all target lesions) or a partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Approximately 1 year
Secondary	Duration of Response (DoR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	To assess antitumor activity/efficacy by evaluating duration of response (DoR), defined as the time from the first documented complete response or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 to the first documented progressive disease or death due to any cause, whichever occurs first. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.	Approximately 1 year
Secondary	Disease Control Rate (DCR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	To assess antitumor activity/efficacy by evaluating disease control rate (DCR), defined as the proportion of participants in whom a documented complete response, partial response, or stable disease is observed as the best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.	Approximately 1 year
Secondary	Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	To evaluate progression-free survival (PFS), defined as the time from the first dose of NC318 to the first occurrence of documented progressive disease or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	Approximately 1 year
Secondary	Overall Survival (OS)	To evaluate overall survival (OS), defined as the time from the first dose of NC318 to death due to any cause.	Approximately 1 year
Secondary	Maximum Plasma Concentration (Cmax) of NC318	To evaluate the Maximum Plasma Concentration (Cmax) of NC318	Days 1, 2, and 3 of Cycles 1 and 5 and Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 21. Each cycle is 7 days during Cycles 1-8 and 14 days thereafter.
Secondary	Area Under the Curve (AUC) of NC318	To evaluate the Area Under the Curve (AUC) of NC318	Days 1, 2, and 3 of Cycles 1 and 5 and Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 21. Each cycle is 7 days during Cycles 1-8 and 14 days thereafter.
Secondary	Half-life (t1/2) of NC318	To evaluate the half-life (t1/2) of NC318	Days 1, 2, and 3 of Cycles 1 and 5 and Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 21. Each cycle is 7 days during Cycles 1-8 and 14 days thereafter.